Evaluation of the Framingham Risk Score in the European Prospective Investigation of Cancer–Norfolk Cohort<subtitle>Does Adding Glycated Hemoglobin Improve the Prediction of Coronary Heart Disease Events?</subtitle>
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is a continuous relationship between glycated hemoglobin (HbA(1c)) and coronary heart disease (CHD) risk, even below diagnostic thresholds for diabetes mellitus. METHODS: To evaluate the Framingham risk score in a UK population-based prospective cohort (European Prospective Investigation of Cancer [EPIC]-Norfolk) and to assess whether adding HbA(1c) improves the prediction of CHD. Participants aged 40 to 79 years were recruited from UK general practices, attended a health check, and were followed up for CHD events and death. The Framingham risk score was computed for 10,295 individuals with data on age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diabetes mellitus, and smoking status. We developed a Cox proportional hazards regression model with the original Framingham covariates and then added HbA(1c) to determine whether this improved the prediction of CHD. Model discrimination was compared by using area under the receiver operating characteristic curves (AUROCs), and the correctness of reclassification was determined by calculating the net reclassification improvement and the integrated discrimination improvement. The main outcome measures were CHD-related hospital admission and death. RESULTS: A total of 430 men and 250 women developed CHD during 8.5 years of follow-up. The AUROC for the original Framingham risk score was 0.71. Using the Framingham variables with coefficients fitted from the EPIC-Norfolk data, the AUROC was 0.72 for men and 0.80 for women, compared with 0.73 and 0.80, respectively, in a score including HbA(1c). This difference was significant for men only (P = .005). The net reclassification improvement was 3.4% (P = .06) in men and -2.2% (P = .27) in women. CONCLUSIONS: The Framingham risk score predicts CHD in this cohort. The addition of HbA(1c) made a small but statistically significant improvement to discrimination in men but not in women, without significant improvement in reclassification of risk category.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Ridker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Khaw, K.-T., Wareham, N., Bingham, S., Luben, R., Welch, A., & Day, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00006 · Cited by 974
Self-citationDay, N., Oakes, S., Luben, R., Khaw, K., Bingham, S., Welch, A., & Wareham, N. (1999) · Nature · doi:10.17863/cam.89388 · Cited by 780
Self-citationRosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. V. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073394 · Cited by 761
Levitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2147 · Cited by 668
Empana, J. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.09.002 · Cited by 263
Cited by
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051b4c · Cited by 1,873
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., Kushner, F. G., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.001 · Cited by 1,324
Coronary Artery Calcium Score and Risk Classification for Coronary Heart Disease Prediction
Polonsky, T. S. (2010) · JAMA · doi:10.1001/jama.2010.461 · Cited by 1,119
Erbel, R., Möhlenkamp, S., Moebus, S., Schmermund, A., Lehmann, N., Stang, A., Dragano, N., Grönemeyer, D., Seibel, R., Kälsch, H., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.030 · Cited by 771
Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk
Cooney, M. T., Dudina, A. L., & Graham, I. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.020 · Cited by 436
Cardiovascular Disease Risk Assessment: Insights from Framingham
D’Agostino Sr., R. B., Pencina, M. J., Massaro, J. M., & Coady, S. (2013) · Global Heart · doi:10.1016/j.gheart.2013.01.001 · Cited by 329
Risk assessment tools for identifying individuals at risk of developing type 2 diabetes
Buijsse, B., Simmons, R. K., Griffin, S. J., & Schulze, M. B. (2011) · Epidemiologic Reviews · doi:10.1093/epirev/mxq019 · Cited by 297
“We previously reported that improvement in discrimination by glycated hemoglobin (HbA1c) over the Framingham prediction model for coronary heart disease was significant comparing C statistics but not using net reclassification improvement (22) and that even small improvements in discrimination were reflected in C stat…”
MethodSelf-citationAssessment of Claims of Improved Prediction Beyond the Framingham Risk Score
Tzoulaki, I. (2009) · JAMA · doi:10.1001/jama.2009.1757 · Cited by 276
Glycated hemoglobin measurement and prediction of cardiovascular disease
Di Angelantonio, E., Gao, P., Khan, H., Butterworth, A. S., Wormser, D., Kaptoge, S., Kondapally Seshasai, S. R., Thompson, A., Sarwar, N., Willeit, P., et al. (2014) · JAMA · doi:10.1001/jama.2014.1873 · Cited by 231
Damen, J. A., Pajouheshnia, R., Heus, P., Moons, K. G. M., Reitsma, J. B., Scholten, R. J. P. M., Hooft, L., & Debray, T. P. A. (2019) · BMC Medicine · doi:10.1186/s12916-019-1340-7 · Cited by 250
Cooney, M. T., Dudina, A., D'Agostino, R., & Graham, I. M. (2010) · Circulation · doi:10.1161/circulationaha.109.852756 · Cited by 222
Cardiovascular risk assessment scores for people with diabetes: a systematic review
Chamnan, P., Simmons, R. K., Sharp, S. J., Griffin, S. J., & Wareham, N. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1454-0 · Cited by 176
“An example from our previous research illustrates some of these analytical approaches [ 34 ].”
ResultSelf-citationRevisiting the links between glycaemia, diabetes and cardiovascular disease
Sattar, N. (2013) · Diabetologia · doi:10.1007/s00125-012-2817-5 · Cited by 163
Ferket, B. S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.434 · Cited by 134
Use of reclassification for assessment of improved prediction: an empirical evaluation
Tzoulaki, I., Liberopoulos, G., & Ioannidis, J. P. A. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr013 · Cited by 70
Ikeda, F., Doi, Y., Ninomiya, T., Hirakawa, Y., Mukai, N., Hata, J., Shikata, K., Yoshida, D., Matsumoto, T., Kitazono, T., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-164 · Cited by 67
Metadata
- Authors
- Simmons, R. K.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2008-06-09
- Volume
- 168
- Issue
- 11
- Pages
- 1209
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1999313909
- Cited by
- 75
- References
- 10
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.